People: Threshold Pharmaceuticals Inc (THLD.PH)

THLD.PH on Philadelphia Stock Exchange

3.72USD
30 Jan 2015
Change (% chg)

$-0.01 (-0.27%)
Prev Close
$3.73
Open
$3.80
Day's High
$3.80
Day's Low
$3.72
Volume
994
Avg. Vol
2,582
52-wk High
$5.52
52-wk Low
$2.59

Search Stocks

Summary

Name Age Since Current Position

Harold Selick

59 Chief Executive Officer, Director

Robert Simon

79 2012 Senior Vice President - Regulatory Affairs and Quality Assurance

Joel Fernandes

44 2011 Vice President - Finance, Controller

Nipun Davar

46 2011 Vice President - Pharmaceutical Development and Manufacturing

Tillman Pearce

57 2012 Chief Medical Officer

Jeffrey Bird

54 2008 Independent Director

Bruce Cozadd

50 2005 Independent Director

David Hoffmann

69 2007 Independent Director

Wilfred Jaeger

58 2001 Independent Director

George Parker

75 2004 Independent Director

David Parkinson

63 2010 Independent Director

Laura Hansen

IR Contact

Biographies

Name Description

Harold Selick

Dr. Harold E. Selick, Ph.D., is Chief Executive Officer, Director of Threshold Pharmaceuticals Inc. From June 2002 until July 2007, Dr. Selick was a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, Inc. (now PDL BioPharma, Inc., or PDL) he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab), which was developed and commercialized by Roche for treating kidney transplant rejection. Dr. Selick serves on the board of directors of PDL, a public company and currently serves as Chairman of the Board of Directors of Catalyst Biosciences, a privately-held drug discovery and development company, serves as a director of InteKrin Therapeutics, a clinical-stage, privately-held biopharmaceutical company, and also serves as a director of Protagonist Therapeutics, a privately-held biotechnology company. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Robert Simon

Mr. Robert L. Simon is Senior Vice President - Regulatory Affairs and Quality Assurance of Threshold Pharmaceuticals, Inc. Prior to April 2012, Mr. Simon served in various positions at OSI Pharmaceuticals (acquired by Astellas Pharmaceuticals), most recently as a Corporate Officer and Executive Vice President of Pharmaceutical Development, from January 2002 to July 2011, where he worked on the registration of Tarceva (erlothnib) in second and third line non-small cell lung cancer and pancreatic cancer. From July 2000 to December 2001, Mr. Simon served as Vice President of Global Regulatory Affairs at Gilead Sciences. From January 1987 to July 2000, Mr. Simon held various positions at Bristol Myers-Squibb, most recently as Vice President of chemistry, manufacturing and controls, or CMC. From November 1981 to December 1986, Mr. Simon held positions in regulatory affairs and chemistry at Syntex Pharmaceuticals. Mr. Simon received his B.S. degree in chemistry from California State University at San Jose.

Joel Fernandes

Mr. Joel A. Fernandes is Vice President - Finance, Controller of Threshold Pharmaceuticals Inc. Prior to May 2011, Mr. Fernandes served as Senior Director, Finance and Controller. Mr. Fernandes served as Associate Director of Finance at Theravance, Inc. from January 2005 to March 2006, Senior Manager of Corporate Finance at KLA-Tencor from August 2002 to January 2005 and Assistant Controller of ALZA Corporation from 1999 to 2002. Mr. Fernandes has been a Certified Public Accountant since 1996 and has a Masters in Accountancy from Manchester College, Indiana.

Nipun Davar

Dr. Nipun Davar Ph.D., Vice President - Pharmaceutical Development and Manufacturing of Threshold Pharmaceuticals, Inc. Prior to October 2011, Dr. Davar was the Vice President of Pharmaceutical Sciences at Transcept Pharmaceuticals from November 2006 to August 2011, where he led the Pharmaceutical Sciences group and pharmaceutical development of Intermezzo (low dose sublingual zolpidem) for the treatment of middle of the night insomnia. From March 1996 to October 2006, Dr. Davar held various leadership positions at ALZA the most recent being Senior Director and Research Fellow. At ALZA, he led multidisciplinary teams for the development of Jurnista® (OROS™ hydormorphone) and Invega® (OROS™ paliperidone). Dr. Davar received his Ph.D. in Pharmaceutical Sciences from the University of Maryland and MBA from the Wharton School at the University of Pennsylvania.

Tillman Pearce

Dr. Tillman Pearce, M.D., is Chief Medical Officer of Threshold Pharmaceuticals, Inc. Dr. Pearce served as Chief Medical Officer of KaloBios Pharmaceuticals, Inc., from 2007 through 2011, and since 2011 has been an oncology consultant. Prior to KaloBios, Dr. Pearce was a Senior Director at PDL BioPharma, Inc. from 2002 to 2007 and a Medical Director in the Oncology Business Unit at Sanofi-Synthelabo from 1997 to 2002. He has also held research positions in oncology at Sandoz and Novartis. Dr. Pearce holds a B.A. in philosophy from Tulane University and an M.D. from the Medical College of Georgia.

Jeffrey Bird

Dr. Jeffrey W. Bird, M.D., Ph.D., is Independent Director of Threshold Pharmaceuticals Inc. Dr. Bird is a Managing Director of Sutter Hill Ventures, a venture capital firm based in Palo Alto, California. Dr. Bird was previously Senior Vice President, Business Operations at Gilead Sciences, where he oversaw business development and commercial activities. Dr. Bird received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School. Dr. Bird is currently a board member of Horizon Pharma, Inc., a public company, and a number of private biotechnology companies.

Bruce Cozadd

Mr. Bruce C. Cozadd is Independent Director of Threshold Pharmaceuticals Inc. He joined Jazz Pharmaceuticals plc at its inception and was appointed Chairman and Chief Executive Officer in April 2009. From 2004 until 2009, Mr. Cozadd served as Jazz Pharmaceuticals’ Executive Chairman. Prior to co-founding Jazz Pharmaceuticals, Mr. Cozadd served in various executive management positions with ALZA Corporation from 1991 until its acquisition by Johnson & Johnson in 2001. At the time of the merger, Mr. Cozadd was serving as Executive Vice President and Chief Operating Officer of ALZA, with responsibility for research and development, manufacturing, and sales and marketing. Prior to joining ALZA, he was in the Corporate Finance Health Care group at Smith Barney, Harris Upham & Co. Inc. He serves on the board of directors of Jazz Pharmaceuticals, Inc., Cerus Corp., The Nueva School and Stanford Hospital and Clinics. He received his B.S. from Yale University and his M.B.A. from Stanford University. The company board of directors believes that Mr. Cozadd’s leadership experience at other life sciences companies gives him a breadth of knowledge and a unique perspective on the industry.

David Hoffmann

Mr. David R. Hoffmann is Independent Director of Threshold Pharmaceuticals Inc. Mr. Hoffmann is retired from ALZA Corporation (now a Johnson & Johnson company) where he held the positions of Vice President and Treasurer from 1992 to until his retirement in October 2002, Vice President of Finance from 1982 to 1992 and Director of Accounting/Finance from 1976 to 1982. Mr. Hoffmann is currently Chief Executive Officer of Hoffmann Associates, a multi-group company specializing in cruise travel and financial and benefit consulting. He serves on the board of directors of DURECT Corporation. Mr. Hoffmann holds a B.S. in Business Administration from the University of Colorado. The company board of directors believes that Mr. Hoffman’s financial knowledge and industry experience are to the board, particularly with respect to his service on the audit committee.

Wilfred Jaeger

Dr. Wilfred E. Jaeger, M.D., is Independent Director of Threshold Pharmaceuticals Inc. He has been a Partner of Three Arch Partners, a venture capital firm, since 1993. Dr. Jaeger serves on the board of directors of North American Scientific, Inc. and a number of private companies. Dr. Jaeger received his B.S. from the University of British Columbia, his M.D. from the University of British Columbia School of Medicine and his M.B.A. from Stanford University. The company board of directors has determined to nominate Dr. Jaeger for election as a director as it believes that Dr. Jaeger’s financial and medical knowledge and experience are to the board, particularly with respect to his service on the audit and compensation committees.

George Parker

Dr. George G. C. Parker, Ph.D., is Independent Director of Threshold Pharmaceuticals Inc. Dr. Parker is the Dean Witter Distinguished Professor of Finance (Emeritus) and previously Senior Associate Dean for Academic Affairs and Director of the MBA Program, Graduate School of Business, Stanford University. Dr. Parker joined the faculty at Stanford University in 1973. He serves on the board of directors of iShares Mutual Funds, Tejon Ranch Company, Colony Financial, Inc. and First Republic Bank and a number of private companies, and was formerly a director of Continental Airlines, Inc. and Netgear, Inc. Dr. Parker received his B.A. from Haverford College and his M.B.A. and Ph.D. from Stanford University.

David Parkinson

Dr. David Ross Parkinson, M.D., is Independent Director of Threshold Pharmaceuticals Inc. He is the president and chief executive officer of Nodality, a South San Francisco-based biotechnology company. Prior to 2007, Dr. Parkinson was senior vice president of Oncology Research and Development at Biogen Idec, vice president of Oncology Development at Amgen and vice president of Global Clinical Oncology Development at Novartis. Dr. Parkinson also worked at the National Cancer Institute from 1990 to 1997, serving as chief of the Investigational Drug Branch, then as action associate director of the Cancer Therapy Evaluation Program. He has also held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center at Tufts University School of Medicine. Dr. Parkinson received his M.D. as gold medalist from the University of Toronto Faculty of Medicine in 1977, with Internal Medicine and Hematology/Oncology training in Montreal at McGill University and in Boston at New England Medical Center. Dr. Parkinson is a past chairman of the Food and Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA’s Cody Medal. He is a past president of the International Society of Biological Therapy and past editor of the Journal of Immunotherapy. He currently serves on the National Cancer Policy Forum of the Institute of Medicine. He has recently completed a term on the FDA’s Science Board as well as a term on the board of directors of the American Association of Cancer Research (AACR). He continues to serve as Chairman of the AACR Finance Committee. The company board of directors has determined to nominate Dr. Parkinson for election in part because it believes it benefits from Dr. Parkinson’s medical knowledge and experience, especially in the field of oncology, and his industry perspective.

Laura Hansen

Basic Compensation

Name Fiscal Year Total

Harold Selick

2,300,760

Robert Simon

910,855

Joel Fernandes

--

Nipun Davar

678,648

Tillman Pearce

1,048,370

Jeffrey Bird

--

Bruce Cozadd

--

David Hoffmann

--

Wilfred Jaeger

--

George Parker

--

David Parkinson

--

Laura Hansen

--
As Of 30 Dec 2013

Options Compensation

Search Stocks